• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Proscia Launches AI Solution to Advance Precision Medicine

by Jasmine Pennic 09/10/2025 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know: 

– Proscia®, a pathology AI company, has announced the launch of Proscia Aperture™, a new precision medicine solution designed to automatically identify eligible patients for clinical trials at the moment of diagnosis. 

– The AI-powered tool aims to tackle one of healthcare’s most significant challenges: connecting patients with life-saving therapies and accelerating the development of new treatments.

Transforming Pathology Data Into Real-Time Insights

Despite major advancements in medicine, fewer than one in ten cancer patients enroll in clinical trials, and many miss out on potentially life-saving therapies. While laboratories hold a unique position at the intersection of pathology, molecular, and clinical data, this wealth of information has largely been disconnected from the drug development process. Proscia Aperture aims to bridge this gap by using AI to turn routine pathology data into real-time insights.

How Aperture Works

Proscia Aperture uses AI to analyze tissue images, AI-derived biomarkers, molecular results, and clinical records from a global network of laboratories. The company’s Concentriq® platform is expected to deliver more than 8 million pathology diagnoses this year, providing a rich source of data. The system generates critical evidence for regulatory submissions, companion diagnostic development, and payer negotiations, while also identifying eligible candidates for clinical trials.

New Revenue Stream for Laboratories

The solution also leverages Proscia’s extensive real-world data repository, which contains over 12 million tissue images along with corresponding clinical and genomic records. Patient privacy is strictly protected through de-identification and stringent governance.

For participating academic medical centers, healthcare systems, and reference laboratories, Proscia Aperture offers a significant new revenue stream. It elevates pathology from a simple diagnostic function to a strategic, research-driving center. This helps laboratories broaden their service offerings, strengthen their competitive position, and thrive in an environment of shrinking margins and workforce shortages.

“One of the hardest realities in precision medicine is that too many patients never have the chance to benefit from breakthrough therapies,” said Suso Platero, former Chief Scientific Officer at Discovery Life Sciences. “Pathology data holds the keys to changing this. By unlocking insights at the moment of diagnosis, we can ensure that scientists have the understanding they need to bring the next treatments to market while giving patients a greater opportunity to access them.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Artificial Intelligence, Clinical Trials, Precision Medicine, Proscia

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Interview

The AI Paradox in Healthcare: Notable CEO Shares Why Moving Too Slowly is a Greater Risk

Most-Read

Pfizer and Trump Administration Announce Landmark Agreement to Lower Drug Costs

Pfizer and Trump Administration Announce Landmark Agreement to Lower Drug Costs

KLAS Report: Epic's Native Ambient Speech Tool Reshapes Customer AI Strategies

KLAS Report: Epic’s Native Ambient Speech Tool Reshapes Customer AI Strategies

Epic Unveils MyChart Central and New APIs to Advance Interoperability at Open@Epic

Epic Outlines Roadmap for Next-Generation Data Sharing at Open@Epic

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

RevSpring to Acquire Kyruus Health, Creating a Unified Patient Experience

RevSpring to Acquire Kyruus Health, Creating a Unified Patient Experience

Oracle Confirms Layoffs in Kansas City

Oracle Confirms Layoffs in Kansas City

Philips Future Health Index 2025: AI and Digital Tech Can Help Solve Cardiac Care Crisis

Philips Future Health Index 2025: AI and Digital Tech Can Help Solve Cardiac Care Crisis

Optain Health Secures $26M to Advance AI-Powered Retinal Screening

Optain Health Secures $26M for AI-Powered Retinal Screening

Sutter Health and Epic Launch "Sutter Sync" to Optimize Remote Chronic Care

Sutter Health and Epic Launch “Sutter Sync” to Optimize Remote Chronic Care

Patient Square Capital Acquires Premier in $2.6B Deal

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |